TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01676259
Drug: Gemcitabine+nab-Paclitaxel
Normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Gemcitabine+nab-Paclitaxel
Study: NCT00517257
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg orally once daily for 24 weeks
Study: NCT00584896
Drug: PB127 for Injectable Suspension
Normalized name: PB127
DrugBank: PB127 (DB06208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.062 mg/kg continuous IV infusion (100-250 mL/hr) during echocardiography, not to exceed 60 minutes infusion, single dose.
Study: NCT01092065
Drug: AFQ056 with L-dopa
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hard gelatin capsule to be taken bid for six weeks
Study: NCT00617539
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01908972
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2mg/kg/day for 16weeks
Study: NCT04042935
Drug: Alpha Lipoic Acid
Normalized name: Alpha lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage II-IVB HNSCC patients receiving concurrent systemic therapy and radiation in the definitive, adjuvant, or palliative setting will receive ALA according to their prescribed dose level. ALA will be taken orally or per feeding tube. It will start 1 week prior to the start of CRT, continue on through CRT, and then continue for 2 weeks after the completion of CRT. Patients will be given dosing diaries to document date and time of each drug administration as well as any missed doses. They will also have weekly visits to report AEs and concurrent medications, have a history and physical exam, report VAS pain scores and OMAS scores, and fill FACT-HN surveys.
Study: NCT00450385
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m2 on day 1 for 6 to 8 cycles
Study: NCT00450385
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone 40 mg/m2 orally days 1-5, repeated every 21 days for 6 to 8 cycles.
Study: NCT00450385
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1 for 6 to 8 cycles
Study: NCT04284150
Drug: Dexmedetomidine; Midazolam;
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment of supraventricular tachycardia in patients with non-cardiac surgery by dexmedetomidine during the perioperative period
Study: NCT05278637
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81mg/day x 4 weeks, Aspirin 325mg/day x 4 weeks. or Aspirin 325mg/day x 4 weeks, Aspirin 81mg/day x 4 weeks.
Study: NCT05278637
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 90mg BID x 4 weeks
Study: NCT00133731
Drug: Otamixaban (XRP0673)
Normalized name: Otamixaban
DrugBank: Otamixaban (DB06635)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00133731
Drug: Unfractionated Heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01486810
Drug: Lisdexamfetamine
Normalized name: Lisdexamfetamine
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be titrated to the tolerated dose over a two week period, with a maximum of 140mg daily, and then maintained on the highest tolerated dose for four weeks
Study: NCT00493220
Drug: SC HYLENEX and Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single, subcutaneous, 150 U dose of HYLENEX; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
Study: NCT00862108
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mg/kg dose: 0.7\~1.2mg/kg PO daily morning intake 8 weeks
Study: NCT00493220
Drug: SC Placebo and Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single, subcutaneous injection of 1 mL 0.9% sodium chloride solution; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
Study: NCT01415128
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once a day dosing of Omeprazole (40 mg) for 8 days
Study: NCT01415128
Drug: Rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of Rosiglitazone (8 mg) for 1 day
Study: NCT04136184
Drug: Inotersen
Normalized name: INOTERSEN
DrugBank: Inotersen (DB14713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inotersen by subcutaneous injection
Study: NCT04136184
Drug: Eplontersen
Normalized name: EPLONTERSEN
DrugBank: Eplontersen (DB16199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplontersen by subcutaneous injection
Study: NCT00881218
Drug: Regadenoson
Normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regadenoson 400 micrograms will be administered IV bolus via an antecubital cannula.
Study: NCT01286688
Drug: Terbinafine Hydrochloride Tablets, 250 mg
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.
Study: NCT00005578
Drug: dexrazoxane hydrochloride
Normalized name: Dexrazoxane Hydrochloride
DrugBank: Dexrazoxane (DB00380)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005578
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005578
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005578
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02908477
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mg/m2. Experimental arm only.
Study: NCT02908477
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg/m2. Standard arm only.
Study: NCT03159702
Drug: Evomela
Normalized name: Evomela
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 140 mg/m\^2/day IV on Day -6 for patients who are \< 60 years of age. 70 mg/m\^2/day IV on Day -6 For patients who are ≥60 years or have a HCT-CI score of \>3
Study: NCT03159702
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/ m\^2/day intravenous on Days: -5 -4, -3, -2
Study: NCT00000478
Drug: atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000478
Drug: nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000478
Drug: diltiazem
Normalized name: Diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000478
Drug: isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03095274
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab, 1500 mg Q4W for 12 months.
Study: NCT03095274
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab 75 mg Q4W for up to 4 doses/cycles.
Study: NCT01964898
Drug: Nicotine patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
Study: NCT00276965
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline or placebo for sertraline starting at 25 mg per day, up to maximum of 200 mg per day
Study: NCT00276965
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium or placebo for lithium starting at 150 mg per day; target dose of 900mg per day. Maximum dose based on clinical response and serum levels (maximum serum level of 1.2 mEq/L).
Study: NCT03483246
Drug: Fecal Microbiota Transplantation (FMT)
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The colonoscopy for FMT will be planned as soon as possible and never more than 5 weeks after inclusion visit.~After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.~The patient will then receive either FMT (frozen preparation of 50g of stools in 300ml of physio, see donor section for details) or sham transplantation (FMT vehicle) in the cecum.
Study: NCT00397358
Drug: Extraneal (7.5% icodextrin) Peritoneal Dialysis Solution
Normalized name: Icodextrin Peritoneal Dialysis Solution
DrugBank: Icodextrin (DB00702)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03395132
Drug: betamethasone (Lianbang Beisong®) cream
Normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The active ingredient of betamethasone (Lianbang Beisong®) cream is Betamethasone hydrate. The pack size of betamethasone (Lianbang Beisong®) cream is 15g.
Study: NCT02524717
Drug: JNJ-56021927
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-56021927 240 milligram (mg) orally once on Day 1.
Study: NCT03958071
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nintedanib initiators
Study: NCT03958071
Drug: Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone initiators
Study: NCT01150474
Drug: Belladonna and Opium Suppositories
Normalized name: belladonna alkaloids / opium Rectal Suppository
DrugBank: Opium (DB11130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belladonna (16.2 mg) and opium (60 mg) suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
Study: NCT01856023
Drug: High Dose Interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01856023
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02345746
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: infusion over 12 hours via HAI
Study: NCT02345746
Drug: Folinic Acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: as a 2-hour infusion via HAI on day 2
Study: NCT02345746
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Following Folinic Acid as a continuous infusion over 48 hours on days 2, 3
Study: NCT03447951
Drug: Para-Toluenesulfonamide
Normalized name: Para-toluenesulfonamide
DrugBank: p-Toluenesulfonamide (DB17299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total dose of PTS100 in this study, the expected accumulated dose in the treatment duration, depends on the patient's tumour size. For each patient, up to 4 tumors, each not exceeding 8.8 cm in diameter, are selected for treatment by the joint decision of the investigator and the radiologist. The total dose is defined as the accumulated dose in treatment duration. The total dose is assigned as 30% of TTV for each patient and maximum TTV should be less than 366 cm3.
Study: NCT03790787
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin as Jardiance® 25 mg film-coated tablets for oral administration
Study: NCT03790787
Drug: Dorzagliatin
Normalized name: Dorzagliatin
DrugBank: Dorzagliatin (DB15123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucokinase activator currently under development
Study: NCT03798678
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03798678
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03798678
Drug: Telaglenastat Hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Telaglenastat (DB15232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03047837
Drug: ASA
Normalized name: ASA
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm C (experimental arm) Treatment: active ASA + placebo MET Dose: 100 mg, 1 tablet daily + 1 tablet twice a day (BID) Duration: 12 months
Study: NCT03047837
Drug: MET
Normalized name: Met
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm B (experimental arm) Treatment: placebo ASA + active MET Dose: 1 tablet daily+ 850 mg, 1 tablet twice a day (BID) Duration: 12 months
Study: NCT00359840
Drug: darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00366678
Drug: Pentavac
DrugBank: AVAC (DB05441)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Pentavac was administered by intramuscular injection 0.5 ml into the anterolateral thigh muscle of the right leg at 2, 3, and 4 months (infant series) and 12 months of age (toddler dose).
Study: NCT00675701
Drug: lixivaptan
Normalized name: Lixivaptan
DrugBank: Lixivaptan (DB06666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules
Study: NCT00675701
Drug: moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets
Study: NCT01307631
Drug: Akt Inhibitor MK2206
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00884663
Drug: Candesartan
Normalized name: Candesartan
DrugBank: Candesartan (DB13919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan cilexitil tablets, 16 mg once daily
Study: NCT00884663
Drug: propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol hydrochloride capsules 160 mg once daily, slow release formulation
Study: NCT03947125
Drug: Buprenorphine transdermal patch on knee joint
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Conventionally buprenorphine transdermal patch had been applied to anterior chest wall or upper arm. But author had applied buprenorphine transdermal patch to painful knee joint in knee osteoarthritic patients. This research is about the effect, adverse effects, and compliance of comparison conventional chest applied buprenorphine transdermal patch group with painful knee joint applied group in knee osteoarthritic patients.
Study: NCT00823303
Drug: Paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mcg daily, adjusted to achieve 40-60% PTH suppression
Study: NCT00823303
Drug: Calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25 mcg daily, adjusted to achieve 40-60% PTH suppression
Study: NCT00150332
Drug: linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01710592
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01710592
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01710592
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02901496
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab infusion will be administered monthly (8 mg/kg body weight i.v., maximun 800 mg). Each subject will receive 3 infusions during the study period.
Study: NCT01702181
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1% concentration of tacrolimus.
Study: NCT01862120
Drug: Dose D1 of interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
Study: NCT01862120
Drug: Dose D2 of Interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
Study: NCT01677390
Drug: SGN-75
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-2 mg/kg IV every 21 days
Study: NCT01677390
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg PO daily
Study: NCT03368963
Drug: Nanoliposomal Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03543202
Drug: Transversus abdominis plane block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: will receive 20ml bupivacaine for Transversus abdominis plane block and intravenous patient controlled analgesia
Study: NCT03543202
Drug: local infiltration anesthesia
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: will receive 20ml bupivacaine for local infiltration anesthesia and intravenous patient controlled analgesia
Study: NCT02273739
Drug: Enasidenib
Normalized name: Enasidenib
DrugBank: Enasidenib (DB13874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enasidenib tablets administered orally once a day in 28-day treatment cycles until disease progression or unacceptable toxicities.
Study: NCT00749879
Drug: Proellex
Normalized name: guaiacolsulfonate / hydrocodone bitartrate Oral Solution [Prolex DH]
DrugBank: Telapristone acetate (DB05253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg capsule administered once orally after subjects have been fed; 25 mg capsule administered once orally while subjects are fasting; 2, 25 mg capsules administered once orally after subjects have been fed; 2, 25 mg capsules administered once orally while subjects are fasting; and 2, 25 mg capsules administered once orally while subjects are fasting
Study: NCT01805596
Drug: clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01805596
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01862120
Drug: Dose D3 of interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
Study: NCT00234936
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01375842
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered as IV infusion at eight dose levels (0.01, 0.03, 0.1, 0.3, 1, 3, 10, 20 mg/kg) in dose escalation cohort and at a dose which result in total drug exposure \</= exposures achieved at the MTD or MAD, will be selected for expansion cohort.
Study: NCT03804931
Drug: 5-Aminosalicylic acid(5-ASA) and/or Prednisone
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine and/or Prednisone
Study: NCT04405674
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 200mg administered intravenously (IV) on Day 1 of each 21-day cycle
Study: NCT04405674
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles
Study: NCT04405674
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed 500mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle
Study: NCT04405674
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 7.5mg/kg administered intravenously (IV) on Day 1 of each 21-day cycle
Study: NCT04405674
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel 260mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles
Study: NCT01875991
Drug: Etanercept via Autoinjector A
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Autoinjector A is a hand-held, reusable, electromechanical device used with a single-use disposable cassette preassembled with an etanercept 50-mg prefilled syringe.
Study: NCT01875991
Drug: Etanercept via Autoinjector B
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Autoinjector B is a single-use, spring-loaded, self-contained autoinjector preassembled with an etanercept 50-mg prefilled syringe.
Study: NCT00612794
Drug: exenatide once weekly
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous injection, once weekly
Study: NCT01106352
Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
DrugBank: Radium Ra 223 dichloride (DB08913)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpharadin (Radium-223 dichloride) is administered intravenously as a bolus injection.